ANN ARBOR, Mich., Jun 17, 2008 – Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced plans to initiate a 40 patient U.S. Phase II clinical trial to study the use of Cardiac Repair Cells (CRCs), a mixture of stem and progenitor cells derived from a patient’s own bone marrow, for the treatment of dilated cardiomyopathy (DCM), a severe form of chronic heart failure. Aastrom is now authorized under U.S. Food & Drug Administration
Continue reading: Aastrom to Initiate Phase II Clinical Trial Using Cardiac Repair Cells
ANN ARBOR, Mich., May 5, 2008 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that its Board of Directors will withdraw its proposal to shareholders for approval of the grant of discretionary authority to Aastrom’s Board of Directors to amend the Company’s Restated Articles of Incorporation to effect a reverse stock split. A Special Meeting of Shareholders had been convened on April 8, 2008 and adjourned
Continue reading: Aastrom Biosciences Board of Directors Withdraws Reverse Stock Split Proposal
ANN ARBOR, Mich., Apr 17, 2008 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced encouraging data from the first two compassionate use patients treated with the Company’s autologous stem cell therapy for dilated cardiomyopathy (DCM), a type of severe chronic heart failure. Hans Michael Klein, M.D., Professor of Cardiac Surgery at the Dusseldorf University Hospital in Dusseldorf, Germany performed the first human application of Aastrom’s Cardiac
Continue reading: Aastrom Biosciences Announces Stem Cell Results
Loading ...